Cargando…
Preclinical profile of cabazitaxel
First-generation taxanes have changed the treatment paradigm for a wide variety of cancers, but innate or acquired resistance frequently limits their use. Cabazitaxel is a novel second-generation taxane developed to overcome such resistance. In vitro, cabazitaxel showed similar antiproliferative act...
Autores principales: | Vrignaud, Patricia, Semiond, Dorothée, Benning, Veronique, Beys, Eric, Bouchard, Hervé, Gupta, Sunil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207555/ https://www.ncbi.nlm.nih.gov/pubmed/25378905 http://dx.doi.org/10.2147/DDDT.S64940 |
Ejemplares similares
-
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013) -
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
por: Fumoleau, Pierre, et al.
Publicado: (2013) -
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010) -
Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011) -
Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)